argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
30 jul 2015 - 07:00
Statutaire naam
argenx SE
Titel
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
Bericht
Collaboration demonstrates potential of ARGX-110 in overcoming treatment resistance
in chronic myelogenous leukemia (CML)
Preclinical results published in Science Translational Medicine
Breda, the Netherlands/Ghent, Belgium, 30 July 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors.
Datum laatste update: 01 september 2024